Back to Journals » Cancer Management and Research » Volume 12

Patients of Myelodysplastic Syndrome with Mild/Moderate Myelofibrosis and a Monosomal Karyotype are Independently Associated with an Adverse Prognosis: Long-Term Follow-Up Data

Authors Wang N, Xu H, Li Q, Fang X, Liu J, Sui X, Zhang L, Jiang Y, Wang X

Received 19 April 2020

Accepted for publication 25 June 2020

Published 16 July 2020 Volume 2020:12 Pages 5881—5891


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Eileen O'Reilly

Na Wang, 1– 3 Hongzhi Xu, 1, 2 Qing Li, 1, 2 Xiaosheng Fang, 1, 2 Jie Liu, 1, 2 Xiaohui Sui, 1, 2 Lingyan Zhang, 1, 2 Yujie Jiang, 1, 2 Xin Wang 1– 5

1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, People’s Republic of China; 2Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, People’s Republic of China; 3School of Medicine, Shandong University, Jinan, Shandong 250012, People’s Republic of China; 4Shandong Provincial Engineering Research Center of Lymphoma, Jinan, Shandong 250021, People’s Republic of China; 5National Clinical Research Center for Hematologic Diseases, Jinan, Shandong 250021, People’s Republic of China

Correspondence: Xin Wang
Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, No. 324 Jingwu Road, Jinan, Shandong 250021, People’s Republic of China
Tel +8613156012606
Fax +86-531-87068707

Purpose: The aim of our study was to evaluate the clinical characteristics of myelodysplastic syndrome (MDS) patients with concomitant mild-to-moderate myelofibrosis (MF), and to assess its independent prognostic role in MDS patients diagnosed by World Health Organization 2016 classification (WHO2016C) with long-term follow-up.
Patients and Methods: A total of 157 patients with primary MDS associated with or without MF were examined retrospectively with long-term follow-up. MF graded as MF-1/MF-2 was defined as “mild/moderate”. Cytogenetics testing and fluorescence in situ hybridization (FISH) were also conducted in all MDS patients.
Results: Thirty-four (21.7%) of 157 MDS patients had MF. Also, 24 (15.3%) MDS patients based on WHO2016 criteria were defined as MF-1 and 10 (6.4%) as MF-2. MDS patients with MF-1/2 had a higher prevalence of death (p=0.002), leukemic progression (p=0.013), O blood type (p=0.039) as well as less hypercellular proliferation (p< 0.001) and less supportive treatment (p=0.003) compared with those without mild/moderate MF. Cytogenetics testing did not show a significant difference between MDS patients with and without MF. Multivariate analyses showed that MF (mild/moderate), a monosomal karyotype (MK) and % bone-marrow blasts were independently associated with shorter overall survival (OS) and progression-free survival (PFS). Age was an independent indicator of the adverse OS of MDS patients. Compared with those without MF, MDS patients with mild/moderate MF were significantly associated with worse OS and PFS in MK-negative subgroups and relatively low-risk Revised International Prognostic Scoring System for Myelodysplastic Syndromes (IPSS-R) stratification in long-term follow-up.
Conclusion: Mild/moderate myelofibrosis and monosomal karyotype are independent indicators of a poor clinical outcome in MDS patients. In long-term follow-up, MDS with mild/moderate MF can be a prognostic marker for MDS patients with a specific MK stratification and IPSS-R stratification.

Keywords: myelodysplastic syndromes, myelofibrosis, prognosis, cytogenetics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]